WESTBURY, N.Y.--(BUSINESS WIRE)--Vasomedical, Inc. (“Vasomedical”) (OTC: VASO.OB), a world leader in the noninvasive treatment of cardiovascular diseases, today announced a reorganization of its Board of Directors to realign its leadership to better position the company for a more diversified business portfolio, including its exclusive sales representative agreement for select diagnostic imaging products recently signed with GE Healthcare. Mr. Simon Srybnik, upon his appointment as Acting Chairman of the Board, said that “Vasomedical’s strategy of growth includes exploration of new and exciting opportunities to meet current and future needs of the worldwide medical marketplace. Restructuring our Board at this time should enable the company to realize its growth potential and to achieve greater shareholder value. I look forward to the active involvement of our directors as we begin to undertake this additional direction in close collaboration with GE Healthcare.”
